BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Propel Kinase Biology Understanding to Increase Selectivity\, 
 Overcome Resistance and Find the Optimal Combination Partner to Develop B
 est and First-in-Class Kinase Targeted Drugs\n\nThe kinase drug discovery
  field is at a pivotal moment\, with recent breakthroughs from industry l
 eaders such as Biogen\, A-Alpha Bio\, and Proxygen paving the way for exc
 iting new approaches in targeting kinases\, particularly in targeted prot
 ein degradation.\n\nHowever\, with ongoing challenges including selectivi
 ty and resistance in small molecule inhibitors\, these hurdles limit the 
 therapeutic applications and call for in-depth discussions focused on inn
 ovative future strategies for kinase targeted drugs.\n\nJoin us at the 3r
 d Kinase Targeted Drug Discovery Summit\; the premier\, target-specific c
 onference designed to provide you with ground-breaking insights to revolu
 tionize your kinase biology.\n\nDiscover cutting-edge developments in sma
 ll molecule therapeutics\, including PROTACs\, molecular glues\, and allo
 steric inhibitors. Don't miss your opportunity to enhance drug selectivit
 y\, tackle resistance head-on\, and identify optimal combination partners
 . Lead the charge in creating first-class kinase-targeted drugs that can 
 ultimately combat disease indications and transform patient outcomes!\n\n
 URLs:Tickets: https://go.evvnt.com/2698121-2?pid=185Brochure: https://go.
 evvnt.com/2698121-3?pid=185\n\nTime: 7:30 AM - 2:45 PM\n\nSpeakers: Aleks
 ey Gerasyuto\, Vice President\, Drug Discovery\, Schrodinger\, Bekim Bajr
 ami\, Associate Scientific Director\, Biogen\, Charbel Moussa\, Scientifi
 c Director\, KeifeRX\, Douglas Thomson\, Director and Head\, Medicinal Ch
 emistry\, Proxygen\, John Brognard\, Senior Investigator\, National Cance
 r Institute (NCI) in NIH\, Kimberly Rizzolo\, Principal Scientist\, Novar
 tis\, Lars Van Der Veen\, Chief Scientific Officer\, iOnctura\, Mark Fitz
 gerald\, Director\, Chemistry\, Nested Therapeutics\, Matthew L. Meyerso\
 ,n Director\, Center for Cancer Genomics\, Dana-Farber Cancer Institute\,
  Randolph Lopez\, Chief Technology Officer\, A-Alpha Bio\, Rayees Rahman\
 , Chief Executive Officer\, Harmonic Discovery\, Susan Paprcka\, Principa
 l Investigator\, Arcus Biosciences\, Tim Owens\, Senior Vice President an
 d Head\, Research\, Alumnis\n
DTEND:20250212T144500
DTSTAMP:20260512T223115Z
DTSTART:20250211T073000
LOCATION:Hilton Boston Back Bay\, 40\, Dalton Street\, Boston\, Massachuse
 tts\, 02115\,
SEQUENCE:0
SUMMARY:Propel Kinase Biology Understanding to Increase Selectivity\, Over
 come Resistance and Find the Optimal Combination Partner to Develop Best 
 and First...
UID:b0898d33-9027-48e3-a250-3b9e5ac08609
END:VEVENT
END:VCALENDAR